No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ZNTL240621C12500
- 1.00
- +0.21+26.58%
15min DelayClose May 31 15:59 ET
1.00High1.00Low
1.00Open0.79Pre Close5 Volume27 Open Interest12.50Strike Price500.00Turnover77.02%IV10.27%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry1.00Time Value100Contract SizeAmericanOptions Type0.4278Delta0.1860Gamma19.80Leverage Ratio-0.0222Theta0.0024Rho8.47Eff Leverage0.0107Vega
Intraday
- 5D
- 1D
News
Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NEW YORK and SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small
Express News | Zentalis Pharmaceuticals Inc -on and Effective May 24, Board Increased Its Size From Six to Seven Directors
Express News | Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.d., to Board of Directors
Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial
Zentalis Pharmaceuticals (ZNTL) said final results from a phase 1 trial of azenosertib plus gemcitabine in relapsed or refractory osteosarcoma resulted in clinically meaningful increase in event-free
Zentalis Pharmaceuticals to Present Promising Results From Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced the presentation of final results from a Phase 1 trial of azenosertib and gemcitabine in relapsed or refractory (R/R) osteosarcoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Comments
The satisfactory 2.7 years cash runway is overshadowed by increased cash burn rate of 19%. The firm's potential to raise funds for growth via new shares may entail dilution of existing ones. Close monitoring of Zentalis Pharmaceuticals' cash burn situation advised.
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Gainers:
• $Enphase Energy(ENPH.US$ +8.2% (earnings reports)
• $Zentalis Pharmaceuticals(ZNTL.US$ +7.6% (announces $25 mln equity investment from Pfizer (PFE); enters into development collaboration for ZN-c3)
• $Ternium(TX.US$ +6.1% (earnings reports)
• $PureCycle Technologies(PCT.US$ +5% (SEC concludes investigation without further action)
• $Alliance Resource(ARLP.US$ +4.7% (increases dividend; provides prelim qtrly results)
• $Digital World Acquisition Corp(DWAC.US$ +4.5% (cu...
• $Enphase Energy(ENPH.US$ +8.2% (earnings reports)
• $Zentalis Pharmaceuticals(ZNTL.US$ +7.6% (announces $25 mln equity investment from Pfizer (PFE); enters into development collaboration for ZN-c3)
• $Ternium(TX.US$ +6.1% (earnings reports)
• $PureCycle Technologies(PCT.US$ +5% (SEC concludes investigation without further action)
• $Alliance Resource(ARLP.US$ +4.7% (increases dividend; provides prelim qtrly results)
• $Digital World Acquisition Corp(DWAC.US$ +4.5% (cu...
14
1
Upgrades
• $Banc of California(BANC.US$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers(CFR.US$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger(GWW.US$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc(INVH.US$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp(PCB.US$: Raymond James Upgrades to Outperform from Market Perfor...
• $Banc of California(BANC.US$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers(CFR.US$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger(GWW.US$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc(INVH.US$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp(PCB.US$: Raymond James Upgrades to Outperform from Market Perfor...
7
Read more